A Compelling Risk/Reward Seen In Momenta Pharmaceuticals
October 11, 2016 at 14:01 PM EDT
Barclays sees a compelling risk/reward in Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) citing the Copaxone 40mg trial. The firm sees ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.